Ventilatory Strategy to Prevent Atelectasis During Bronchoscopy Under General Anesthesia: A Multicenter Randomized Controlled Trial (Ventilatory Strategy to Prevent Atelectasis -VESPA- Trial).


Journal

Chest
ISSN: 1931-3543
Titre abrégé: Chest
Pays: United States
ID NLM: 0231335

Informations de publication

Date de publication:
Dec 2022
Historique:
received: 16 03 2022
revised: 20 06 2022
accepted: 23 06 2022
pubmed: 9 7 2022
medline: 15 12 2022
entrez: 8 7 2022
Statut: ppublish

Résumé

Atelectasis negatively influences peripheral bronchoscopy, increasing CT scan-body divergence, obscuring targets, and creating false-positive radial-probe endobronchial ultrasound (RP-EBUS) images. Can a ventilatory strategy reduce the incidence of atelectasis during bronchoscopy under general anesthesia? Randomized controlled study (1:1) in which patients undergoing bronchoscopy were randomized to receive standard ventilation (laryngeal mask airway, 100% Fio Seventy-six patients were analyzed, 38 in each group. The proportion of patients with any atelectasis according to chest CT scan at time 2 was 84.2% (95% CI, 72.6%-95.8%) in the control group and 28.9% (95% CI, 15.4%-45.9%) in the VESPA group (P < .0001). The proportion of patients with bilateral atelectasis at time 2 was 71.1% (95% CI, 56.6%-85.5%) in the control group and 7.9% (95% CI, 1.7%-21.4%) in the VESPA group (P < .0001). At time 2, 3.84 ± 1.67 (mean ± SD) bronchial segments in the control group vs 1.21 ± 1.63 in the VESPA group were deemed atelectatic (P < .0001). No differences were found in the rate of complications. VESPA significantly reduced the incidence of atelectasis, was well tolerated, and showed a sustained effect over time despite bronchoscopic nodal staging maneuvers. VESPA should be considered for bronchoscopy when atelectasis is to be avoided. ClinicalTrials.gov; No.: NCT04311723; URL: www. gov.

Sections du résumé

BACKGROUND BACKGROUND
Atelectasis negatively influences peripheral bronchoscopy, increasing CT scan-body divergence, obscuring targets, and creating false-positive radial-probe endobronchial ultrasound (RP-EBUS) images.
RESEARCH QUESTION OBJECTIVE
Can a ventilatory strategy reduce the incidence of atelectasis during bronchoscopy under general anesthesia?
STUDY DESIGN AND METHODS METHODS
Randomized controlled study (1:1) in which patients undergoing bronchoscopy were randomized to receive standard ventilation (laryngeal mask airway, 100% Fio
RESULTS RESULTS
Seventy-six patients were analyzed, 38 in each group. The proportion of patients with any atelectasis according to chest CT scan at time 2 was 84.2% (95% CI, 72.6%-95.8%) in the control group and 28.9% (95% CI, 15.4%-45.9%) in the VESPA group (P < .0001). The proportion of patients with bilateral atelectasis at time 2 was 71.1% (95% CI, 56.6%-85.5%) in the control group and 7.9% (95% CI, 1.7%-21.4%) in the VESPA group (P < .0001). At time 2, 3.84 ± 1.67 (mean ± SD) bronchial segments in the control group vs 1.21 ± 1.63 in the VESPA group were deemed atelectatic (P < .0001). No differences were found in the rate of complications.
INTERPRETATION CONCLUSIONS
VESPA significantly reduced the incidence of atelectasis, was well tolerated, and showed a sustained effect over time despite bronchoscopic nodal staging maneuvers. VESPA should be considered for bronchoscopy when atelectasis is to be avoided.
TRIAL REGISTRY BACKGROUND
ClinicalTrials.gov; No.: NCT04311723; URL: www.
CLINICALTRIALS RESULTS
gov.

Identifiants

pubmed: 35803302
pii: S0012-3692(22)01227-2
doi: 10.1016/j.chest.2022.06.045
pii:
doi:

Banques de données

ClinicalTrials.gov
['NCT04311723']

Types de publication

Randomized Controlled Trial Multicenter Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1393-1401

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2022 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.

Auteurs

Moiz Salahuddin (M)

Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.

Mona Sarkiss (M)

Department of Anesthesia and Peri-Operative MedicineThe University of Texas MD Anderson Cancer Center, Houston, TX.

Ala-Eddin S Sagar (AS)

Department of Onco-Medicine, Banner MD Anderson Cancer Center, Gilbert, AZ.

Ioannis Vlahos (I)

Thoracic Imaging Department, Division of Diagnostic Imaging, Texas MD Anderson Cancer Center, Houston, TX.

Christopher H Chang (CH)

Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.

Archan Shah (A)

Department of Onco-Medicine, Banner MD Anderson Cancer Center, Gilbert, AZ.

Bruce F Sabath (BF)

Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.

Julie Lin (J)

Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.

Juhee Song (J)

Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX.

Teresa Moon (T)

Department of Anesthesia and Peri-Operative MedicineThe University of Texas MD Anderson Cancer Center, Houston, TX.

Peter H Norman (PH)

Department of Anesthesia and Peri-Operative MedicineThe University of Texas MD Anderson Cancer Center, Houston, TX.

George A Eapen (GA)

Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.

Horiana B Grosu (HB)

Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.

David E Ost (DE)

Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.

Carlos A Jimenez (CA)

Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.

Gouthami Chintalapani (G)

Siemens Medical Solutions USA, Inc., Malvern, PA.

Roberto F Casal (RF)

Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address: rfcasal@mdanderson.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH